Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Estudio de seguimiento clínico posterior a la comercialización (PMCF) de Zimmer Continuum Metal sobre polietileno (MoP)

24 de septiembre de 2026 actualizado por: Zimmer Biomet

Estudio de seguimiento clínico prospectivo posterior a la comercialización del sistema acetabular de metal continuo sobre polietileno

This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.

Tipo de estudio

De observación

Inscripción (Actual)

195

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • California
      • Fremont, California, Estados Unidos, 94538
        • Sah Orthopaedic Associates
    • Colorado
      • Denver, Colorado, Estados Unidos, 80204
        • Denver Health Medical Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients from surgeons medical practice who are candidates for primary hip arthroplasty.

The study population will be comprised of 300 males and females who require primary total hip arthroplasty. Subjects will be enrolled at up to 7 clinical sites. Subjects must be geographically accessible throughout the study and be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will be offered informed consent, and eligibility will be determined based upon the inclusion/exclusion criteria.

Descripción

Inclusion Criteria

  • Patient is 18 to 75 years of age, inclusive.

  • Patient is skeletally mature.

  • Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:

    • Avascular necrosis (AVN)
    • Osteoarthritis
    • Inflammatory arthritis (i.e., Rheumatoid arthritis)
    • Post-traumatic arthritis
  • Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).

  • Patient has moderate, marked or disabling pain.

  • Patient is willing and able to provide written informed consent.

  • Patient is willing and able to cooperate in the required post-operative therapy.

  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.

  • Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.

Exclusion Criteria:

  • The patient is:

    • A prisoner
    • Mentally incompetent or unable to understand what participation in the study entails
    • A known alcohol or drug abuser
    • Anticipated to be non-compliant
  • The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.

  • The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.

  • The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.

  • The patient is known to be pregnant.

  • The patient is unwilling or unable to give consent or to comply with the follow-up program.

  • The patient has received an investigational drug or device within the previous 6 months.

  • The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.

  • The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.

  • The patient has osteoradionecrosis in the affected hip joint.

  • The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.

  • The patient has known local bone tumors and/or cysts in the operative hip.

  • The patient has a Body Mass Index (BMI) > 40.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Continuum Acetabular System

Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System

Used in primary hip arthroplasty

Otros nombres:
  • Reemplazo total de cadera, artroplastia total de cadera, cadera primaria

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Survivorship
Periodo de tiempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Based on removal or intended removal of the device and determined using the Kaplan-Meier method.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Safety / Adverse Events
Periodo de tiempo: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects.

Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Pain and Function / HHS
Periodo de tiempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Pain and function will be measured using the Harris Hip Score self assessment.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Pain and Function / OHS
Periodo de tiempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Pain and function will be measured using the Oxford Hip Score self assessment.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Health Status / SF-12
Periodo de tiempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Health status will be measured using the SF-12 self assessment.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Health Status / Radiographic Parameters
Periodo de tiempo: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

X-rays will be evaluated for acetabular cup angle, acetabular cup migration, femoral stem position, femoral stem subsidence and femoral stem shift.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Metal Ion / Cobalt
Periodo de tiempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Metal Ion / Chromium
Periodo de tiempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Metal Ion / Titanium
Periodo de tiempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Renal Function / BUN
Periodo de tiempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Renal Function / Creatinine
Periodo de tiempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Renal Function / GFR
Periodo de tiempo: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Hillary Overholser, Zimmer Biomet

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

29 de marzo de 2011

Finalización primaria (Actual)

17 de julio de 2026

Finalización del estudio (Actual)

17 de julio de 2026

Fechas de registro del estudio

Enviado por primera vez

25 de febrero de 2011

Primero enviado que cumplió con los criterios de control de calidad

28 de febrero de 2011

Publicado por primera vez (Estimado)

2 de marzo de 2011

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CMU2010-02H

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .